Home / Health / Millions of Australians May Soon Access Subsidized Wegovy
Millions of Australians May Soon Access Subsidized Wegovy
12 Jan
Summary
- Wegovy may soon be subsidized on Australia's PBS for eligible adults.
- Strict criteria include cardiovascular disease and weight thresholds.
- This aims to improve equity and reduce out-of-pocket costs for many.
The Australian government is preparing to subsidize the weight-loss medication Wegovy on the Pharmaceutical Benefits Scheme (PBS), potentially making it more accessible to millions. This decision follows a recommendation from the Pharmaceutical Benefits Advisory Committee for adults with obesity and established cardiovascular disease. Eligible individuals must have experienced a serious cardiovascular event and meet specific weight requirements.
Health Minister Mark Butler has indicated that price negotiations with the drug's manufacturer, Novo Nordisk, will commence. Currently, many Australians face significant out-of-pocket expenses, with costs potentially reaching $4,000 to $5,000 annually. Butler emphasized that improving access to Wegovy is a critical health and equity issue, as it suppresses appetite and aids significant weight loss.
While a timeline for the PBS listing is unconfirmed, once implemented, patients will benefit from reduced costs, potentially aligning with the current maximum PBS price of $25 per prescription. Experts highlight Wegovy's dual benefit of supporting weight loss and preventing future cardiovascular issues, though they also stress that medication alone isn't a sole solution to Australia's obesity rates.
